SYMBIOTEC PHARMALAB LTD IPO: Company Review, Subscription and Allotment Updates

2026-08-22 — Company overview and issue details

SYMBIOTEC PHARMALAB LTD IPO (ABOUT THE COMPANY)

SYMBIOTEC PHARMALAB LTD – COMPANY BACKGROUND

Symbiotec Pharmalab Ltd is into the development and manufacture of active pharma ingredients (APIs), which are key inputs for pharmaceutical preparations. It also makes key inputs for nutritional products and specialty products. It caters to the domestic and the international markets. The company is today a backward integrated API manufacturing platform, with substantial control over its supply chain. It has several regulatory approvals, including from the FAD, US. It has 2 manufacturing facilities with peak chemical synthesis capacity of 584.67 MTPA and fermentation capacity of 300 KL. It is a key support segment for the pharmaceutical and the nutrition industry.

The promoters of Symbiotec Pharmalab Ltd are Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP. The IPO will be a combination of a fresh issue of shares and an offer for sale (OFS) component. The fresh issue funds will be used for prepayment of loans availed by the company and for general corporate purposes. The OFS is being done by the promoter shareholders and investor shareholders. The issue is being lead-managed by JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory; while MUFG Intime India Private Ltd is the IPO registrar.

HIGHLIGHTS OF THE IPO ISSUE OF SYMBIOTEC PHARMALAB LTD

Here are the key highlights of the public issue of Symbiotec Pharmalab Ltd.

The IPO is open from August 24th, 2026 to August 27th, 2026. It has a face value of ₹2 per share and the IPO price band has been fixed in the range of ₹938 to ₹988 per share.

The IPO of Symbiotec Pharmalab Ltd will be a combination of a fresh issue of shares and an offer for sale of shares by the investor shareholders.

The Fresh Issue portion of the IPO comprises the issue of 15,21,261 shares (15.21 lakh shares), which at the upper price band of ₹988 per share, translates into a fresh issue size of ₹150.30 crore.

The offer for sale (OFS) portion of the IPO comprises the sale of 1,62,65,181 shares (162.65 lakh shares), which at the upper price band of ₹988 per share, translates into an OFS size of ₹1,607 crore.

Therefore, the overall IPO will comprise of the fresh issue portion and offer for sale (OFS) portion comprising of 1,77,86,442 shares (177.86 lakh shares), which at the upper price band of ₹988 per share translates into overall issue size of ₹1,757.30 crore.

Due to dilutive impact of the fresh issue and the offer for sale (OFS) by promoters, the promoter stake in the company will reduce from 36.41% pre-IPO to 33.28% post-IPO.

The IPO of Symbiotec Pharmalab Ltd will be listed on the NSE and the BSE on the IPO mainboard. The anchor allocation happened on August 21, 2026.

KEY DATES, INVESTOR ALLOCATION, AND LOT SIZES

Here are the key dates pertaining to the IPO of Symbiotec Pharmalab Ltd

Data Source: Company RHP

Investors can apply either through their existing trading account or the ASBA application can be directly logged through the internet banking account. This can only be done through the authorized list of self-certified syndicate banks (SCSB).

The table below captures the gist of the allocation to various categories.

Data Source: Security Parameters Filing (NSE)

The anchor portion, is carved out of the QIB portion and the QIB portion available in the IPO offer has been reduced proportionately. Please note that the above shares are final and may differ marginally from the original announcement.

Here is a quick look at the lot sizes applicable for the IPO of Symbiotec Pharmalab Ltd for various categories of investors.

It may be noted here that for the B-HNI category and for the QIB (qualified institutional buyer) category, there are no upper limits applicable. (1 Lot = 15 shares)

FINANCIAL HIGHLIGHTS OF SYMBIOTEC PHARMALAB LTD

The table captures the key financials of Symbiotec Pharmalab Ltd for last 3 financial years.

Data Source: Company RHP filed with SEBI (FY refers to Apr-Mar period)

The net margins and the EBITDA margins of the company have been healthy and stable over the last 3 years. The ROE has been on the lower side, but that is more due to the large equity base of the company, although the borrowings are quite low. Due to the capital-intensive nature of the business, the asset turnover ratio is relatively low.

VALUATION METRICS OF SYMBIOTEC PHARMALAB LTD IPO

At the IPO price of ₹988 (upper band), the stock gets discounted at a P/E ratio of 50.7X, based on the latest FY26 EPS of ₹19.00. If one were to other similar companies into the API business, the valuations are actually reasonable. However, the ROE is relatively on the lower side, which could prove to be a cap on the valuations of the company.

Apart from the financial numbers, there are also some other areas where Symbiotec Pharmalab Ltd has an edge. It continues to enjoy a leadership position in steroidal hormone APIs and corticosteroid APIs. The API business is a long-term relationship business and the company has established stable links in India and globally. Its vertically integrated platform ensures better control over the supply chain, which is key to delivery. It has the ability to enhance TAM without additional investments. It does look reasonably priced in the API space, although the valuation multiples may be capped.

2026-08-22 — Anchor allocation

SYMBIOTEC PHARMALAB LTD IPO (ANCHOR ALLOCATION 28.87%)

BRIEF ON ANCHOR ALLOCATION OF SYMBIOTEC PHARMALAB LTD

The anchor issue of Symbiotec Pharmalab Ltd saw a strong response on 21st August 2026 with 28.87% of the IPO size absorbed by anchors. Out of 1,84,50,838 shares (184.51 lakh shares) on offer in the IPO; anchors picked up 53,25,909 shares (53.26 lakh shares) accounting for 28.87% of the total IPO size. The entire anchor allocation was made at the upper end of the price band of ₹988 per share. This includes the face value of ₹2 per share plus a share premium of ₹986 per share. The anchor bidding opened and closed on 21st August 2026.

KEY POINTS TO NOTE IN THE ANCHOR ALLOCATION PROCESS

Here are the key details pertaining to the anchor bidding of Symbiotec Pharmalab Ltd

An anchor investor in an IPO is a qualified institutional buyer (QIB) like a foreign portfolio investor or mutual fund or insurance company or a sovereign fund which invests before the IPO is made available to the public as per SEBI regulations. It helps in price discovery.

MAJOR ANCHOR ALLOCATION INVESTORS IN SYMBIOTEC PHARMALAB LTD

On 21st August 2026, Symbiotec Pharmalab Ltd allotted 53,25,909 shares to a total of 34 anchor investors. The allocation was done at the upper IPO price band of ₹988 per share which resulted in overall anchor allocation of ₹526.20 crore. The anchors have already absorbed 28.87% of the total issue size of ₹1,822.94 crore, after factoring in the employee discount offered in the IPO, if any.

Listed below are the Top 10 IPO anchor investors who accounted for anchor collection of ₹336.01 crores, or, 63.86% of the overall anchor allocation of shares, one trading day ahead of the IPO of Symbiotec Pharmalab Ltd. The individual anchor allocation of top-10 investors is indexed descending on the number of shares allotted.

Data Source: BSE Filings (Value Allocated is ₹ in Crore)

The detailed and comprehensive report on the anchor allocation, with the mutual fund portion segregated, can be accessed on BSE by clicking on the link below.

https://www.bseindia.com/downloads/UploadDocs/Notices/Attach/Symbiotec_Company_Anchor_Intimation_Letter$357b55d4-8dab-4f85-ad19-d332dcc01eec.pdf

Out of the 53,25,909 shares allocated to the anchors in the IPO, there was an allocation of 31,98,480 shares made to mutual funds regulated by SEBI. This anchor allocation to mutual funds was spread across 19 MF schemes of 11 asset management companies (AMC). Mutual funds accounted for 60.06% of the overall anchor allocation.

Out of the 53,25,909 shares allocated to the anchors in the IPO, there was an allocation of 4,25,130 shares made to 3 life insurance companies regulated by IRDAI, representing 7.98% of the total anchor allocation. The remaining anchor allocation was spread across FPIs, ODIs, SIFs, and alternate investment funds (AIFs).

NEXT STEPS IN SYMBIOTEC PHARMALAB LTD IPO

Post the closure of the IPO subscription on 27th August 2026, the basis of allotment will be finalized on 28th August 2026 and the refunds will be initiated on 31st August 2026. In addition, the demat credits are expected to also happen on 31st August 2026 and the stock will list on 01st September 2026 on the NSE and the BSE. The credits to the demat account to the extent of shares allotted will happen by the close of 31st August 2026 under ISIN (INE899I01028).

2026-08-27 — Day-3 subscription update

Symbiotec Pharmalab Ltd (Day-3 Final Subscription at 71.26 times)

SYMBIOTEC PHARMALAB LTD - IPO SUBSCRIPTION STATUS ON DAY-3

As of 7.30 pm on 27th August 2026, out of the 131.25 lakh shares on offer in the IPO (excluding anchor portion), Symbiotec Pharmalab Ltd saw bids for 9,352.50 lakh shares. This implies an overall subscription of 71.26X at a macro level. The granular break-up of subscriptions at close of Day-3 of the IPO of Symbiotec Pharmalab Ltd was as under:

The subscriptions were led by the QIB Investors followed by the HNI / NII investors and the Retail investors in that order. QIB bids and NII bids typically gather most of the momentum only on the last day. That was the case in this IPO too. Both, the QIB portion and the HNI / NII portion saw bulk of the institutional, corporate and funded subscriptions come in on the last day of the IPO. The company saw steady anchor participation a day ahead of the IPO opening with 28.87% of the IPO size absorbed by anchor investors. Here is the category-wise subscription. The overall subscription ratio excludes anchor portion.

Data Source: NSE / BSE (as of close of Day-3 of the IPO)

The IPO of Symbiotec Pharmalab Ltd was open up to August 27, 2026, and has closed for subscription as of the close of trading hours on August 27, 2026. The subscription ratios presented in the table above represent the final subscription numbers for each category and also for the IPO overall. Generally, the listing price of the IPO and the post-listing performance tend to get influenced by the extent of oversubscription of the IPO. However, it must also be noted that a higher subscription is not an automatic guarantee of a strong listing performance for the IPO stock. The final subscription ratio excludes anchor portion. Total bids as of the close (including anchor allocation) stood at ₹92,928.87 crore.

NEXT STEPS IN THE SYMBIOTEC PHARMALAB LTD IPO

Post the closure of the IPO subscription on 27th August 2026, the basis of allotment will be finalized on 28th August 2026 and the refunds will be initiated on 31st August 2026. In addition, the demat credits are expected to also happen on 31st August 2026 and the stock will list on 01st September 2026 on the NSE and the BSE. The credits to the demat account to the extent of shares allotted will happen by the close of 31st August 2026 under ISIN (INE899I01028).

2026-08-28 — Allotment guidance and next steps

Symbiotec Pharmalab Ltd IPO (How to check allotment status)

ABOUT THE SYMBIOTEC PHARMALAB LTD IPO

The IPO of Symbiotec Pharmalab Ltd opened on August 24th, 2026 and closed on August 27th, 2026. The overall IPO comprised of a fresh issue and an offer for sale (OFS) of 1,84,50,838 shares (184.51 lakh shares) worth ₹1,822.94 crore at the upper price band of ₹988 per share. The allotment status will be finalized by end of day (EOD) of August 28, 2026. Here is how to check your allotment status for the IPO of Symbiotec Pharmalab Ltd. You can check IPO status on the BSE website or on the NSE website or on the IPO Registrar website (MUFG Intime India Private Ltd).

CHECKING THE ALLOTMENT STATUS OF SYMBIOTEC PHARMALAB LTD IPO ON BSE WEBSITE

This is a facility available to all mainboard IPOs, irrespective of who the registrar to the issue is. Visit the BSE link for the IPO allotment by clicking on the link below.

https://www.bseindia.com/investors/appli_check.aspx

Once you reach the page, here are the steps to follow.

Under Issue Type – Select Equity Option

Under Issue Name – Select Symbiotec Pharmalab Ltd from the drop-down box

Enter the Application Number / CAF exactly as in the acknowledgement slip OR

Enter your PAN (10-digit alphanumeric) number

Once this is done, you need to click on the Captcha to verify you are not a robot

Finally click on the Search Button

You can use either of the parameters to query; Application / CAF number or Investor PAN.

The allotment status will be displayed on the screen in front of you informing about the number of shares of Symbiotec Pharmalab Ltd allotted into your demat account. You can save a screenshot of the allotment status output for subsequently verifying with the demat account credits.

CHECKING ALLOTMENT STATUS OF SYMBIOTEC PHARMALAB LTD IPO ON NSE WEBSITE

This is a common link for all IPOs. Click on NSE link for IPO allotment as below.

https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids

Once you reach the page, here are the steps to follow.

Under Issue Type – Select Equity & SME IPO Details Option

Under SELECT SYMBOL – Select SYMBIOTEC from the dropdown box

Enter the Application Number / CAF exactly as in the acknowledgement slip AND

Enter your PAN (10-digit alphanumeric) number

Once both are entered, click on the Submit Button

You must input the Application / CAF number and the Investor PAN.

The allotment status will be displayed on the screen in front of you informing about the number of shares of Symbiotec Pharmalab Ltd allotted into your demat account. You can save a screenshot of the allotment status output for tallying with the demat account credits.

CHECKING ALLOTMENT STATUS OF SYMBIOTEC PHARMALAB LTD ON MUFG INTIME INDIA PRIVATE LIMITED (REGISTRAR TO THE IPO)

Here are the steps to follow. Visit the Link Intime registrar website for IPO status by clicking on the link below:

https://in.mpms.mufg.com/Initial_Offer/public-issues.html

There are 4 options available to you to access the allotment status, and you can use any of these options to query.

You can use PAN access. Enter the 10-character alphanumeric income tax permanent account number (PAN). Make it a point to verify your PAN before entering.

The second option is to use Application Number / CAF to query the allotment status in the IPO. The application / CAF number is available on the acknowledgement slip.

You can use DPID-Client ID combination. For NSDL combination is alphanumeric, while for CDSL, combination is numeric. This is available in your demat statement.

You can also query by the combination of your bank account number and IFSC number provided as the IPO mandate bank. It is available on your cheque book.

Finally, click on the SUBMIT button.

In case, you have any issues with the output, register an investor query with Link Intime India Private Ltd. You can either send an email with all requisite details and problem to ipo.helpdesk@in.mpms.mufg.com or you can call on (0)-81081-14949 for voice call.

NEXT STEPS IN THE SYMBIOTEC PHARMALAB LTD IPO

Post the closure of the IPO subscription on 27th August 2026, the basis of allotment will be finalized on 28th August 2026 and the refunds will be initiated on 31st August 2026. In addition, the demat credits are expected to also happen on 31st August 2026 and the stock will list on 01st September 2026 on the NSE and the BSE. The credits to the demat account to the extent of shares allotted will happen by the close of 31st August 2026 under ISIN (INE899I01028).

Interested in applying for this IPO?

SERNET is an Authorised Person of Choice Equity Broking Pvt. Ltd. (SEBI Reg. No. INZ000160131). All broking services — trading, demat and IPO applications — are provided by Choice Equity Broking.

New to Choice FinX? Open a free account →

Already have an account? Log in to Choice FinX →